Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

 Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule
                                  5635(c)(4)

PR Newswire

JERSEY CITY, N.J., Feb. 1, 2013

JERSEY CITY, N.J., Feb. 1, 2013 /PRNewswire/ --Optimer Pharmaceuticals, Inc.
(NASDAQ: OPTR) announced today that on January 31, 2013 the Inducement Award
Sub-Committee of the Compensation, Nominating, and Corporate Governance
Committee of its Board of Directors approved the grant of inducement
restricted stock units covering an aggregate of 6,240 shares of common stock
to 4 new employees.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Each restricted stock unit vests over three years, with one-third of the
shares vesting on the first, second, and third anniversary of the applicable
vesting commencement date, subject to the new employee's continued service
relationship with the Company. Each restricted stock unit is subject to the
terms and conditions of the Company's 2012 Equity Incentive Plan and the
restricted stock unit agreement pursuant to which the award was granted.

The restricted stock units were granted as inducements material to the new
employees entering into employment with Optimer in accordance with NASDAQ
Listing Rule 5635(c)(4).

AboutOptimer Pharmaceuticals
Optimer Pharmaceuticals, Inc.is a global biopharmaceutical company focused on
developing and commercializing innovative hospital specialty products that
have a positive impact on society. Optimer developed DIFICID® (fidaxomicin)
tablets, anFDA-approved macrolide antibacterial drug for the treatment
ofClostridium difficile-associated diarrhea (CDAD) in adults 18 years of age
and older and is commercializing DIFICID in the US and Canada. Optimer also
received marketing authorization for fidaxomicin tablets in theEuropean
Unionwhere its partner,Astellas Pharma Europe, is commercializing
fidaxomicin under the trade name DIFICLIR™. The Company is exploring
marketing authorization in other parts of the world whereC. difficilehas
emerged as a serious health problem, includingAsia. Additional information
can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications
Jason I. Spark, Senior Vice President
(619) 849-6005

SOURCE Optimer Pharmaceuticals, Inc.

Website: http://www.optimerpharma.com
 
Press spacebar to pause and continue. Press esc to stop.